CD38 and Miyoshi myopathy: iDuo-MM CAR-NK cells were designed for maximal targeting of MM cells through the anti-BCMA CAR and via the engagement of hnCD16 with anti-CD38 mAbs, including daratumumab, for a unique dual-targeting approach.